clinical trial · NCT07472647
SYS6090 Combination Therapy in Advanced Lung Cancer
Shanghai JMT-Bio Inc.·phase2·not yet recruiting·n = 596
Non-Small Cell Lung CancerSmall Cell Lung CancerSYS6090 + pemetrexed + platinum-based chemotherapySYS6090 + paclitaxel + platinum-based chemotherapySYS6090 + docetaxelSYS6090 + pemetrexed + bevacizumab + platinum-based chemotherapySYS6090 + SYS6010SYS6090 + etoposide + platinum-based chemotherapySYS6090 + chemotherapy or other anticancer therapy
brief summary
This is an open-label, multi-cohort, multicenter Phase Ib/II clinical study designed to evaluate the safety, tolerability, and efficacy of SYS6090 injection in combination with chemotherapy or chemotherapy and bevacizumab or SYS6010 (an EGFR ADC) in participants with advanced lung cancer.
started
Feb 28, 2026
primary completion
Feb 28, 2029
completion
Feb 28, 2030
last updated
Mar 16, 2026
official title
A Phase Ib/II Study to Evaluate the Safety, Tolerability, and Efficacy of SYS6090 in Combination With Other Therapies in Participants With Advanced Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol